Inzen Therapeutics

Biotechnology ResearchMassachusetts, United States11-50 Employees

Cell loss is a critical source of information that living cells use to shape responses in health and disease. Living cells process and respond to inputs from cells that are dying, either as a normal step in the cycle of cell loss or abnormally under disease conditions. This interplay, the domain of Thanokine(TM) Biology, is a rich and untapped source of insights into how to prevent and treat cancer, immune-inflammatory disorders, fibrotic disorders, and degenerative disease.

Inzen Tx has developed a product platform to interrogate how living cells respond to the information released from dying cells. This discovery of a fundamental, overlooked category of inputs into living cell opens a vast opportunity to develop new strategies to treat some of the most intractable medical problems in cancer, fibrotic and inflammatory disorders, and degenerative diseases. Inzen imagines a future where it is possible to develop curative cancer drugs that drive immunoreactivity in the tumor microenvironment, eradicating tumors. In addition, targeting Thanokines(TM) and associated pathways, Inzen will develop drugs that stop or even resolve fibrosis or stop pathologic inflammation, and therapies that tap into the body’s natural mechanisms for regenerating tissues.

By first expanding the perspective on the inputs that cells respond to in health and disease, and then creating new therapeutic approaches to harness and control the flow of the information encoded in cell turnover, Inzen is opening a vast new frontier of discovery for a broad range of serious diseases.

Sign up for free to view info

Email Format Employee directory